Evaluation of Sch 29,482 in the eradication of Neisseria meningitidis from nasopharyngeal carriers.
AUTOR(ES)
Pugsley, M P
RESUMO
Fifty-eight chronic carriers of Neisseria meningitidis were given 250 mg of Sch 29,482 or placebo orally every 6 h for 4 days. Although 22 of 29 subjects taking Sch 29,482 became culture negative while taking the drug, only five were culture negative 2 weeks posttherapy. There were no significant adverse reactions.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=185560Documentos Relacionados
- Evaluation of single-dose ciprofloxacin in the eradication of Neisseria meningitidis from nasopharyngeal carriers.
- Comparative in vitro activity of Sch 29,482, a new oral penem, against Neisseria gonorrhoeae.
- Clonal diversity of Neisseria meningitidis from a population of asymptomatic carriers.
- Antibiotic Susceptibility Patterns of Neisseria meningitidis Isolates from Patients and Asymptomatic Carriers
- COMPARISON OF METHODS TO IDENTIFY Neisseria meningitidis IN ASYMPTOMATIC CARRIERS
